dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
We asked patients about using—and endocrinologists about prescribing—a connected insulin pen.
Concerns about family or friends getting COVID-19 and about getting COVID-19 oneself increased, as case numbers rose nationally over the summer.
Our research with the ADA reveals severe economic impacts of COVID-19 on Americans with diabetes, including high unemployment and care rationing.
Our fourth COVID-19 survey of U.S. diabetes patients highlights persistent concerns, economic stress, and changing behaviors despite easing lockdowns.
dQ&A reveals how Walmart’s CareZone deal, low mail-order NPS scores, and a pandemic push toward home delivery are reshaping pharmacy apps for diabetes.
Our third COVID-19 survey of U.S. diabetes patients found high infection concern, income loss, care changes, and challenges accessing healthy food and supplies.
Our survey of Canada’s type 1 diabetes community reveals COVID-19’s impact on medication access, diet, exercise, hyperglycemia, and overall well-being.
Our April 2020 dQ&A survey of 4,700 U.S. diabetes patients finds supply chains largely intact yet short-term delays and risky pharmacy visits hinder refills.
